BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 25890386)

  • 1. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
    Wagner B; Freer H; Rollins A; Erb HN
    Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
    Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
    Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
    Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
    Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
    LaFleur RL; Callister SM; Dant JC; Wasmoen TL; Jobe DA; Lovrich SD
    Clin Vaccine Immunol; 2015 Jul; 22(7):836-9. PubMed ID: 25972405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
    LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
    Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks.
    Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D
    Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
    Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
    Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
    Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.
    Hebert D; Eschner A
    Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.
    Rhodes DV; Earnhart CG; Mather TN; Meeus PF; Marconi RT
    Vet J; 2013 Nov; 198(2):412-8. PubMed ID: 23962611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.
    Voordouw MJ; Tupper H; Önder Ö; Devevey G; Graves CJ; Kemps BD; Brisson D
    Vector Borne Zoonotic Dis; 2013 Apr; 13(4):203-14. PubMed ID: 23428088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
    Zhao H; Bao FF; Liu A
    J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.